Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 597, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ijpharm.2021.120345
Keywords
Rifampicin; Tuberculosis; Dry powder inhalers; Safety; Intra-tracheal
Categories
Funding
- Otago Medical Research Foundation (OMRF)
- Education New Zealand (NZIDRS, New Zealand International Doctoral Research Scholarship)
- School of Pharmacy, University of Otago
Ask authors/readers for more resources
Inhaled delivery of high-dose rifampicin was found to be safe for rat lungs and liver, with reduced hepatic burden compared to oral administration and good tolerance to repeated dosing. Tissue evaluation showed no drug-induced toxicity in the lungs, indicating potential for localized and systemic drug delivery without toxicity concerns.
Inhaled delivery of rifampicin has the potential to achieve high drug concentrations in the lung and the blood for efficient treatment of tuberculosis (TB). Due to its existence as polymorphs, in vivo evaluation of the respiratory tract safety of inhalable amorphous and crystalline rifampicin particles, at clinically relevant high-dose, is necessary. This study investigates the lung and liver safety and the tissue distribution of rifampicin after intratracheal administration of high (>= 25 mg/kg) doses of amorphous and crystalline powder formulations to Sprague Dawley rats. Powder formulations were administered by intra-tracheal insufflation to rats. Lung and liver safety were evaluated by histopathology. Serum alanine transaminase (ALT) and aspartate aminotransferase (AST) assays were performed to study the hepatic effects. Rifampicin was quantified in the tissues using LC-MS/MS. Intra-tracheal administration of rifampicin decreased the drug burden on the liver compared to oral administration based on its lower serum ALT activity. Repeated-dose intra-tracheal rifampicin was well tolerated by rats, confirmed by the absence of drug or delivery induced complexities. The histopathological evaluation of rat lungs, after both single and repeated drug administration for seven days, suggested the absence of drug-induced toxicity. Following single intra-tracheal delivery of 50 mg/kg doses, comparable rifampicin concentrations to that from same oral dose were observed in lung, liver, heart and brain. Inhaled delivery of high-dose rifampicin was safe to rat lungs and liver suggesting its potential for localized as well as systemic drug delivery without toxicity concerns.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available